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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Saccharomyces cerevisiae var. boulardii CNCM I-3799 and reducing gastro-
intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 
1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Lesaffre International/Lesaffre Human Care, submitted pursuant to Article 13(5) 
of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, 
Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related 
to Saccharomyces cerevisiae var. boulardii CNCM I-3799 and reducing gastro-intestinal discomfort. The food 
constituent that is the subject of the health claim, S. cerevisiae var. boulardii CNCM I-3799, is sufficiently 
characterised. The claimed effect, reduction of gastro-intestinal discomfort, is a beneficial physiological effect. 
The target population proposed by the applicant is subjects from 18 to 74 years old with bowel discomfort. The 
Panel notes that none of the studies provided for the substantiation of the claim was conducted with the strain 
which is the subject of the claim (S. cerevisiae var. boulardii CNCM I-3799), except for two animal studies and 
one in vitro study. Upon an EFSA request, the applicant indicated that the rest of the studies provided were 
conducted with the strain produced by Biocodex Laboratories (S. cerevisiae var. boulardii HANSEN CBS 
5926). The applicant also stated that the strain, which is the subject of the claim, S. cerevisiae var. boulardii 
CNCM I-3799, is equivalent to S. cerevisiae var. boulardii HANSEN CBS 5926, based on a comparative PCR 
inter-delta element analysis of both strains provided in the application. The Panel considered that the evidence 
provided was insufficient to establish that the strains S. cerevisiae var. boulardii CNCM I-3799 and HANSEN 
CBS 5926 are identical and, upon EFSA request for further information, additional evidence was not provided 
by the applicant. A cause and effect relationship cannot be established between the consumption of S. cerevisiae 
var. boulardii CNCM I-3799 and reducing gastro-intestinal discomfort. © European Food Safety Authority, 
2012 
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SUMMARY 
Following an application from Lesaffre International/Lesaffre Human Care, submitted pursuant to 
Article13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on 
Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific 
substantiation of a health claim related to Saccharomyces cerevisiae var. boulardii CNCM I-3799 and 
reducing gastro-intestinal discomfort. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence, including a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is S. cerevisiae var. boulardii CNCM I-
3799. The Panel considers that S. cerevisiae var. boulardii CNCM I-3799 is sufficiently characterised. 
The claimed effect is reducing gastro-intestinal discomfort. The target population proposed by the 
applicant is subjects from 18 to 74 years old with bowel discomfort. The Panel considers that reducing 
gastro-intestinal discomfort is a beneficial physiological effect. 
None of the studies provided for the substantiation of the claim were conducted with the strain that is 
the subject of the claim (S. cerevisiae var. boulardii CNCM I-3799), except for two animal studies and 
one in vitro study. Upon EFSA’s request for further information, the applicant indicated that the rest of 
the studies provided were conducted with the strain produced by Biocodex Laboratories (S. cerevisiae 
var. boulardii HANSEN CBS 5926), sold under different brands. The applicant also stated that the 
strain, which is the subject of the claim, S. cerevisiae var. boulardii CNCM I-3799, is equivalent to S. 
cerevisiae var. boulardii HANSEN CBS 5926, based on a comparative PCR inter-delta element 
analysis of both strains, provided in the application. The Panel considered that the evidence provided 
was insufficient to establish that the strains S. cerevisiae var. boulardii CNCM I-3799 and HANSEN 
CBS 5926 are identical and, upon EFSA’s request for further information, additional evidence was not 
provided by the applicant. The Panel also considered that in the absence of human data the two animal 
studies and one in vitro study conducted with the strain which is the subject of the claim could not be 
used for the substantiation of the claimed effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship cannot be 
established between the consumption of S. cerevisiae var. boulardii CNCM I-3799 and reduction of 
gastro-intestinal discomfort. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 09/02/2012. The scope of the application was proposed to fall 
under a health claim based on newly developed scientific evidence and including a request for 
the protection of proprietary data. 
 The scientific evaluation procedure started on 30/03/2012. 
 On 26/04/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application, and the clock was stopped on 
30/04/2012, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
 On 21/05/2012, EFSA received the requested information as submitted by the applicant and 
the clock was restarted. 
 During its meeting on 27/06/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Saccharomyces 
cerevisiae var. boulardii CNCM I-3799 and reducing gastro-intestinal discomfort. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to: Saccharomyces cerevisiae var. boulardii 
CNCM I-3799 and reducing gastro-intestinal discomfort. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of S. cerevisiae var. boulardii CNCM I-3799, a positive assessment of its safety, nor a decision on 
whether S. cerevisiae var. boulardii CNCM I-3799 is, or is not, classified as a foodstuff. It should be 
noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
Saccharomyces cerevisiae var. boulardii CNCM I-3799  
and reducing gastro-intestinal discomfort 
 
 
5 EFSA Journal 2012;10(7):2801 
INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address:  
Lesaffre International / Lesaffre Human Care, 137 rue Gabriel Peri, 59700 Marcq en Baroeul, France. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (unpublished Rousseaux et al. 2009 study). 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which a health claim is made is Saccharomyces 
cerevisiae var. boulardii CNCM I-3799, identified as Saccharomyces boulardii CNCM I-3799. 
Health relationship as claimed by the applicant 
According to the applicant, the relationship between the consumption of Saccharomyces cerevisiae 
var. boulardii CNCM I-3799 and maintenance of intestinal comfort has been assessed by evaluating 
the impact of this strain on the different outcomes of Irritable Bowel Syndrome (IBS). The relationship 
between the consumption of the yeast and the claimed effect has been evaluated by assessing its 
impact on the surrogate markers of IBS, particularly abdominal pain, abdominal discomfort, bloating 
and frequency and consistency of stools. Moreover, the adequate or satisfactory relief of abdominal 
discomfort has been assessed, both by physicians and subjects. Beyond that, since IBS induces a 
deterioration of the quality of life of subjects, this outcome has also been evaluated. Thanks to various 
mechanisms of action, S. boulardii CNCM I-3799 significantly enhanced the overall assessment of 
IBS symptoms and the quality of life of subjects, by reducing the abdominal pain and by improving 
the stool frequency and consistency. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Saccharomyces cerevisiae 
var. boulardii CNCM I-3799 helps maintain intestinal comfort”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is male and female, from 18 to 74 years old, with 
bowel discomfort. The applicant has proposed an intake of 1x10
10
 cfu/day. 
ASSESSMENT 
1. CHARACTERISATION OF THE FOOD/CONSTITUENT 
The food constituent that is the subject of the health claim is Saccharomyces cerevisiae var. boulardii 
CNCM I-3799 (hereafter S. cerevisiae var. boulardii CNCM I-3799). It was stated in the application 
that S. cerevisiae var. boulardii CNCM I-3799 was phenotypically characterised by the biochemical 
tests of the BIOLOG
®
 system. Data on genotypic characterisation of S. cerevisiae var. boulardii 
CNCM I-3799, including sequence analysis of the D1/D2 region of the 26S rRNA gene for species 
identification and PCR inter-delta element analysis for strain typing, were provided in the application.  
A culture collection number from the Collection Nationale de Cultures de Microorganismes (CNCM) 
was provided for S. cerevisiae var. boulardii CNCM I-3799. The CNCM is a restricted-access non-
public collection, which has the status of an International Depositary Authority under the Budapest 
Treaty.  
Data on production, variability of viable yeast counts from batch to batch, stability during storage and 
other quality control parameters (appearance, water activity, granulometry, biological and chemical 
safety) of the strain S. cerevisiae var. boulardii CNCM I-3799 were provided. 
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The Panel considers that the food constituent, S. cerevisiae var. boulardii CNCM I-3799, which is the 
subject of the health claim, is sufficiently characterised. 
2. RELEVANCE OF THE CLAIMED EFFECT TO HUMAN HEALTH 
The claimed effect is “helps maintain intestinal comfort”. The target population proposed by the 
applicant is “male and female, from 18 to 74 years old, with bowel discomfort”. 
The Panel considers that reduction of gastro-intestinal (GI) discomfort is a beneficial physiological 
effect. 
3. SCIENTIFIC SUBSTANTIATION OF THE CLAIMED EFFECT 
The applicant performed a literature search in Medline, ScienceDirect, Mary Ann Liebert, Springer 
link, Wiley InterScience, IBIDS, Scirus, and Google scholar with the search terms: “Saccharomyces 
cerevisiae var. boulardii” OR “Saccharomyces boulardii” OR "boulardii" OR "perenterol" OR 
"hansen CBS 5926" AND “digestive comfort” OR “gut microflora” OR “digestive health” OR “gut” 
OR “bowel” OR “digest*”OR “diarrhoea” OR “colitis” OR “diarrhea” OR “fecal microbiota” OR 
“IBS” OR “Irritable bowel syndrome” OR “Syndrôme de l’intestin irritable” OR “SII” OR “Syndrome 
du colon irritable” OR “spastic colon” OR “functional bowel disorder” OR “abdominal pain” OR 
“bloating”.  
According to the applicant, this literature search resulted in the identification of five human studies 
which addressed the effects of S. cerevisiae var. boulardii on functional colopathies (Bennani, 1990), 
on IBS symptoms (Choi et al., 2011; Maupas et al., 1983), on histology and enzymatic activities (Buts 
et al., 1986; Jahn et al., 1996) and on lymphocytes (Jahn et al., 1996) of the intestinal mucosa of 
healthy subjects.  
Animal studies submitted addressed the effect of S. cerevisiae var. boulardii on histology and enzymes 
of the intestinal mucosa (Buts et al., 1986), on stimulation of secretory IgA production (Buts et al., 
1990; Rodriguez et al., 2000) and phagocytic activity (Rodriguez et al., 2000) in the small intestine, on 
adaptation of intestinal mucosa after enterectomy (Buts et al., 1999), on inflammatory markers in a 
model of experimental colitis (Foligné et al., 2010) and on anti-inflammatory and analgesic effects on 
a chemically-induced colitis model (Rousseaux et al., 2009, unpublished).   
In vitro studies addressing effects of S. cerevisiae var. boulardii on immune-related parameters in cell 
cultures (Sougioultzis et al., 2006), and on survival of the strain in simulated GI conditions, adhesion 
to cell lines and cytokine gene expression in cell cultures (van der Aa Kühle et al., 2005; Denis et al. 
2010, unpublished) were also provided.  
The Panel notes that none of the studies provided for the substantiation of the claim were conducted 
with the strain which is the subject of the claim (S. cerevisiae var. boulardii CNCM I-3799), except 
for two animal studies and one in vitro study (Foligné et al., 2010; Rousseaux et al. 2009, unpublished; 
Denis et al. 2010, unpublished).  
Upon an EFSA request, the applicant indicated that the rest of the studies provided were conducted 
with the strain produced by Biocodex Laboratories (S. cerevisiae var. boulardii HANSEN CBS 5926), 
sold under different brand names. The applicant also stated that the strain, which is the subject of the 
claim, S. cerevisiae var. boulardii CNCM I-3799, is equivalent to S. cerevisiae var. boulardii 
HANSEN CBS 5926, based on a comparative PCR inter-delta element analysis of both strains 
provided in the application.  
The Panel considered that this evidence was insufficient to establish that the strains S. cerevisiae var. 
boulardii CNCM I-3799 and HANSEN CBS 5926 are identical and, upon EFSA request for further 
information, additional data were not provided by the applicant. The Panel also considered that in the 
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absence of human data the two animal studies and one in vitro study conducted with the strain which 
is the subject of the claim cannot be used for the substantiation of the claimed effect. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of S. cerevisiae var. boulardii CNCM I-3799 and reduction of gastro-intestinal 
discomfort.   
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, Saccharomyces cerevisiae var. boulardii CNCM I-3799, which is the 
subject of the claim, is sufficiently characterised. 
 The claimed effect is “helps maintain intestinal comfort”. The target population as proposed 
by the applicant is “male and female, from 18 to 74 years old, with bowel discomfort”. 
Reducing gastro-intestinal discomfort is a beneficial physiological effect. 
 A cause and effect relationship cannot be established between the consumption of 
Saccharomyces cerevisiae var. boulardii CNCM I-3799 and reducing gastro-intestinal 
discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Saccharomyces cerevisiae var. boulardii CNCM I-3799 and reducing 
gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial 
No: 327_FR). March 2012. Submitted by Lesaffre International/Lesaffre Human Care. 
REFERENCES 
Bennani A., 1990. [Randomised trial of Saccharomyces boulardii in the treatment of functional 
colopathies]. L’Objective Medical, 73, 56-61 (translation from French provided by the applicant). 
Buts J-P., Bernasconi P., Van Craynest M.P., Maldague P. and de Meyer R., 1986. Response of human 
and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric 
Research, 1986, 192-196.  
Buts J-P., Bernasconi P. and Vaerman J.P., 1990. Stimulation of secretory IgA and secretory 
component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. 
Digestive Diseases and Sciences, 35, 251-256.  
Buts J-P., De Keyser N., Marandi S., Hermans D., Sokal E.M., Chae Y-H.E., Lambotte L., Chanteux 
H. and Tulkens P.M, 1999. Saccharomyces boulardii upgrades cellular adaptation after proximal 
enterectomy in rats. Gut, 1999, 89-96.  
Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.S. and Myung S.J., 2011. A randomized, double-
blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome; 
effect on quality of life. Journal of Clinical Gastroenterology,45,679-683.  
Denis S., Alric M., Pignede G. and Vandekerckove P., 2010 (unpublished). Study of the survival of 
Saccharomyces cerevisiae var. boulardii strain CNCM I-3799 in an artificial digestive environment 
simulating the human intestine. 
Foligné B., Dewulf J., Vandekerckove P., Pignede G. and Pot B., 2010. Probiotic yeasts: anti-
inflammatory potential of various non-pathogenic strains in experimental colitis in mice. World 
Journal of Gastroenterology, 16, 2134-2145. 
Saccharomyces cerevisiae var. boulardii CNCM I-3799  
and reducing gastro-intestinal discomfort 
 
 
8 EFSA Journal 2012;10(7):2801 
Jahn H-U., Ulrich R., Schneider T., Liehr R-M., Schieferdecker H.L., Holst H. and Zeitz M., 1996. 
Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy 
human volunteers. Gigestion, 57, 95-104. 
Maupas J.L., Champemont P., Delforge M. and 1983. Treament of irritable bowel syndrome, double 
blind trial of Saccharomyces boulardii. Medecine et Chirurgie Digestives, 12, 77-79. 
Rodriguez A.C.P., Cara D.C., Fretez S.H.G.G., Cunha F.,Q., Vieira E.C., Nicoli J.R. and Vieira L.Q., 
2000. Saccharomyces boulardii stimulates slgA production and the phagocytic system of 
gnotobiotic mice. Journal of Applied Microbiology, 89, 404-414. 
Rousseaux C., Desreumaux P., Pignede G. and Vadekerckove P., 2009 (unpublished). Study on the 
anti-inflammatory and analgesic properties of the Saccharomyces cerevisiae var. boulardii CNCM 
I-3799 strain. 
Sougioultzis S., Simeonidis S., Bhaskar K.R., Chen X., Anton P., M., Keates S., Pothoulakis C. and 
Kelly C.P., 2006. Saccharomyces boulardii produces a soluble anti-inflammatory factor that 
inhibits NF-κB-mediated IL-8 gene expression. Biochemical and Biophysical Research 
Communications, 343, 69-76. 
van der Aa Kühle A., Skovgaard K. and Jespersen L., 2005. In vitro screening of probiotic properties 
of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. 
International Journal of Food Microbiology, 101, 29-39. 
Saccharomyces cerevisiae var. boulardii CNCM I-3799  
and reducing gastro-intestinal discomfort 
 
 
9 EFSA Journal 2012;10(7):2801 
GLOSSARY / ABBREVIATIONS 
CNCM  Collection Nationale de Cultures de Microorganismes  
GI gastro-intestinal 
IBS irritable bowel syndrome 
PCR polymerase chain reaction 
 
 
 
